NCT06828796

Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Northside Hospital, Inc. · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process

Conditions

• Hematologic Disease and Disorders
• Hematopoietic Cell Transplant

Interventions

Type	Name	Description
DRUG	Tacrolimus	Begins Day -1 and continues to Day +90 or Day +180 after transplant
DRUG	Cyclophosphamide	Given Days +3 and +4 after transplant
DRUG	Mycofenolate mofetil	Given Day 0 to Day +35 after transplant

Timeline

• Start date: 2025-07-03
• Primary completion: 2027-06-30
• Completion: 2028-06-30
• First posted: 2025-02-14
• Last updated: 2026-04-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study